Type 2 or non-insulin-dependent diabetes mellitus (NIDDM) is a common disease and afflicts about 120 million people worldwide. NIDDM accounts for roughly 90% of all cases of diabetes and is characterized by insulin resistance, i.e. the inability of the body to effectively respond to circulating insulin. Key players in insulin signalling pathways that stimulate glycogen synthesis are the protein kinases AKT/PKB (protein kinase B) and glycogen synthase kinase-3 (GSK-3). Activation of AKT/PKB in response to insulin is mediated by phosphatidylinositol 3-kinase together with further kinases, protein kinases D (PDK)-1 and PDK-2 [1, 2]. Active AKT/PKB phosphorylates and, thus, inactivates GSK-3. Consequences of this inactivation may be different for different GSK-3 isozymes and in different tissues such as muscle and liver [3]. Because GSK-3 is responsible for the inactivation of glycogen synthase when this protein is pre-phosphorylated by casein kinase II (CK-2) [4], inactivation of GSK-3 results in the activation of glycogen synthesis.
Therefore, inhibitors of GSK-3 should mimic insulin action and result in enhanced glycogen synthesis and in lower plasma glucose levels. This has been shown, for instance, for lithium chloride (LiCl), a well-known inhibitor of GSK-3, which exerts insulin-like effects on glycogen synthesis and glucose uptake in insulin-sensitive tissues
. In addition, LiCl reduces expression of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase genes, whose expression is suppressed by insulin [7] . Further orchestration by insulin of glucose and lipid metabolism may occur via the transcription factor adipocyte determination-and differentiationdependent factor 1 (ADD-1)/SREBP-1c whose transcriptional activity is also regulated by GSK-3-dependent phosphorylation [8] .
The serine/threonine kinase GSK-3 exists in two isoforms (␣ and ␤) with approximately 98% homology at the catalytic domain [9] . Both isoforms are constitutively active in cells, but cannot completely substitute for each other. Besides glycogen synthase, GSK-3␤ has a plethora of different targets [10] , among them are components of Wnt-, Hedgehog-and other signalling pathways, many transcription factors and proteins involved in regulating apoptosis [11] [12] [13] . Another important target of GSK-3␤ is the microtubule-associated protein [14] . [14, 15] . GSK-3␤ is also involved in the production of amyloid ␤-peptides [16] and, therefore, is considered to play a decisive role in the pathological process of AD [17, 18] [19, 20] .
-hyperphosphorylation occurs early under neuro-degenerative conditions such as Alzheimer's disease (AD) and is thought to promote microtubule disassembly

. Thus, the central role of GSK-3␤ in distinct cell types and especially in the disorders mentioned above renders this enzyme a promising target for the potential treatment of NIDDM, AD and other diseases
Several groups have reported on small-molecule inhibitors of GSK-3␤ (for reviews see [11] [12] [13] 21] ). Most of these (e.g. , SB 216763, hymenaldisine, indirubins, aloisines and paullones) have been described as ATP-competitive GSK-3 inhibitors [13] which, in contrast to previous claims of specificity, were recently found to inhibit, at least partially, one or more additional kinases [22] . Though all these inhibitors were shown to exert many insulin-like effects in vitro and often also in vivo, a common event distinct from normal insulin action which was reported for most of these compounds, is the activation of ␤-catenin signalling [23] [24] [25] . Usually, i.e. in the absence of any stimulus (like Wnt-factors), cytoplasmic ␤-catenin is targeted to proteolytic breakdown by the proteasome (for reviews see [26, 27] [28] . Uncontrolled activation of ␤-catenin was frequently found to be associated with cell proliferation and tumour development [29, 30] .
). Targeting is initiated by binding to the so-called destruction complex (minimally consisting of Axin, GSK-3␤, adenomatous poliposis coli and CK-1␣) followed by phosphorylation at S45 by CK-1 (priming) and subsequent phosphorylation at residues T41, S37 and S33 by GSK-3␤. Phosphorylated ␤-catenin is then ubiquitinylated and degraded. Inhibition of GSK-3␤, consequently, generates hypophosphorylated ␤-catenin which can enter the nucleus, heterodimerize with T-cell factor/lymphoid enhancing factor (TCF/LEF) and act as a transcriptional co-activator
Despite recent progress in understanding insulin signalling, the question of how insulin in the adult organism can act through inhibition of GSK-3␤, while circumventing activation of ␤-catenin and hazardous downstream effects thereof, is not yet completely answered. One mechanism described by Cohen's group [31] suggests inhibition of the interaction of GSK-3 with Axin by FRAT-1 (frequently rearranged in advanced T-cell lymphomas 1), which does not interfere with essential cellular functions of GSK-3.
Alternatively, functionally distinct pools of GSK-3 may be sequestered from each other by interacting proteins as exemplified by the ␤-catenin destruction complex [32, 33] . However [34] . Because emodin is a well-known inhibitor of protein kinases including CK-2 [35, 36] 
, we speculated that derivatives of this lead compound might show altered potency and specificity in inhibiting protein kinases and performed a screening using various in vitro kinase assays. In this study, we show that one representative of our series of novel emodin derivatives, 4-[N-2-(aminoethyl)-amino]-emodin (L4) (Fig. 1), is a potent inhibitor of GSK-3␤. Using various cellular systems to detect functional consequences of GSK-3␤ inhibition, we could demonstrate that compound L4 mimics various aspects of insulin action in an excellent manner, while avoiding transcriptional activation of TCF/LEF target genes via activation of ␤-catenin.
EGF-receptor tyrosine kinase and other kinase assays
Determination of epidermal growth factor receptor (EGFR) tyrosine kinase was performed using an ELISA assay in 96-well format (PRK Assay kit, Sigma) as described recently [38] . EGFR tyrosine kinase (Sigma) [44] were cultured as described [45] . The murine neural stem cell-like cell line C17.2 [46] [41] . Cellular ATP content was determined using the CellTiter-Glo assay as described previously [47] . 
Cytotoxicity assays
Cytotoxicity of the inhibitors was determined by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay as described
Enzymatic measurements and other analytical procedures Preparation of cell lysates
Glycogen synthase assay
The activity of glycogen synthase was determined according to Cross et al. [48] . 
Glutamine synthetase assay
Enzymatic activity of glutamine synthetase was determined with the glutamyltransferase method modified as described by Gebhardt and Williams [49] . In each assay 100 l cell homogenate in Hank's buffered salt solution were used. Cellular protein concentration was measured according to Bradford [50] 
Expression and purification of glutathione S-transferase (GST) fusion proteins
Expression vectors for GST and GST fusion proteins with ␤-catenin residues 536-781, and the cytoplasmic tail of E-cadherin (GST-ECT) have been described [54, 55]. A construct for expressing GST-␤-catenin 400-781 was obtained by inserting a StuI/NotI restriction fragment from pGEX4T1-␤-catenin [54] into the SmaI and NotI sites of pGEX4T1 (Amersham Pharmacia, Freiburg, Germany). GST fusion proteins were
expressed in E. coli BL21 and purified on glutathione sepharose as described [54] except for GST-␤-catenin 400-781, which did not bind to glutathione sepharose and, therefore, was used as crude bacterial lysate. 
Measurements of ␤-catenin activation
Changes in total amounts of ␤-catenin and in levels of hypophosphorylated ␤-catenin indicative of the activation of Wnt signalling in response to inhibition of GSK-3␤ or to the addition of
Molecular docking procedures
The protein ligand docking studies were performed on the basis of the crystal structures of GSK-3␤ in complex with AR-A014418 (pdb entry 1q5k) [58] . [60] . Fig. 1) 
Results
Protein kinase inhibition
Comparing emodin and its derivative 4-[N-2-(aminoethyl)-amino]-emodin (L4) (
At a concentration of 10 M, L4 was found to be almost as effective as SB216763 in inhibiting GSK-3␤ (remaining activity 2% versus 1%). It also inhibits GSK-3␣ (not shown).
Molecular docking studies
More insight into the molecular interactions of the emodin derivative L4 with GSK-3␤ could be obtained from molecular docking studies. The blind docking strategy, which searches for possible binding sites on the complete protein surface area of GSK-3␤ predicts the inhibitor L4 mostly bound in the ATP binding region in 50 independent docking experiments (Fig. 3A). This indicates that L4 preferentially interacts with the ATP-binding site.
A more detailed docking focussed on the ATP binding pocket of GSK-3␤. As shown in Fig. 3B , L4 is predicted to interact with the key residues Asp133 and Val135. These residues are reported to be essential for inhibitor binding [12, 58] 
Fig. 2 Concentration-dependent inhibition of glycogen synthase kinase-3␤ (GSK-3␤) by L4. Activity of GSK-3␤ in response to different concentrations of L4, curve fitting and determination of IC50-values were performed as described in 'Materials and methods'. Enzyme activity is expressed as percentage of the activity measured in the presence of DMSO. Data points (squares) represent means Ϯ S.D. of three independent measurements. The continuous thin line illustrates the result of curve fitting for determination of the IC50-value.
Cytotoxicity studies
Before physiological effects of emodin derivative L4 and other GSK-3 inhibitors were studied in cellular systems, cytotoxicity of these compounds was determined over a wide range of concentrations using the MTT assay. Figure 4A shows [10] . As shown in Table 3 [33] . As shown in Fig. 6A , [62, 63] . In parallel, a concomitant surge in total amounts of ␤-catenin was detected with an antibody recognizing the C-terminus of ␤-catenin (Fig. 6B) (Fig. 6A-C, lanes 11 and 12) . [64] . Western blot analyses of whole cell lysates showed no change in overall levels of ␤-catenin in response to inhibition of GSK-3␤ (Fig. 6E) . Again, this is likely due to high amounts of ␤-catenin present in cell adhesion complexes which prevent detection of the free pool of ␤-catenin induced by the GSK-3␤ inhibitors. Therefore, this signalling-competent pool of ␤-catenin was specifically measured by affinity precipitation (GST-ECT fishing) using a GST fusion protein containing the cytoplasmic tail of E-cadherin, a high affinity binding partner of ␤-catenin [65] . Treatment with SB216763 or Wnt-3␣ led to a strong increase in the amount of ␤-catenin which could be recovered by GST-ECT (Fig. 6D, compare lanes 2, 4, 8, 12 ). As in HEK293 cells, however, L4 produced a relatively minor effect (Fig. 6D,  compare lanes 2, 4, 10) .
A different set of experiments focused on acetate incorporation into newly synthesized fatty acids, because acetyl CoA carboxylase, one of the key enzymes of this pathway, is another important target of GSK-3␤
Fig. 4. Influence of emodin-derivative L4 and of two known inhibitors of GSK-3␤ on (A) viability and (B) cellular ATP levels of cultured hepatocytes. (A) Cytotoxicity determined with the MTT assay. (B) ATP levels of hepatocytes expressed as percentage of DMSO control cultures. In both assays, cultured hepatocytes were exposed to L4 (open circles), TDZD-8 (closed circles) and SB216763 (open squares) for 24 hrs. Values represent means Ϯ S.D. of (A) three or (B) six independent measurements. *, significantly different from controls, P Ͻ 0.01.
Fig. 5 Influence of insulin and different inhibitors of GSK-3␤ on (A) glycogen synthase activity, (B) glycogen synthesis and (C) total glycogen in cultured hepatocytes. (A) Activation of glycogen synthase activity. Cultured hepatocytes were maintained in the presence of insulin (Ins, 10 Ϫ7 M), the inhibitors lithium chloride (Li, 30 mM), L4 (10 M) and SB216763 (SB, 10 M) or in the presence of a combination of insulin with L4 (I ϩ L4) and SB216763 (I ϩ SB) for 90 min. Control cultures (Co) were exposed to the vehicle DMSO. Cells were lysed and the activity of glycogen synthase was measured as described in 'Materials and methods'. Results are expressed as fold-change of activities determined for control cells. Values represent means ϩ S.D. of three independent determinations. *, significantly different from controls, P Ͻ 0.001; **, significantly different from controls, P Ͻ 0.01. (B) Concentrationdependence of the influence of L4 and SB216763 on glycogen synthesis. Cultured hepatocytes were incubated in the presence of inhibitors L4 (open circles) and SB216763 (closed circles) for 60 min. and exposed to [ 14 C]glucose for further 120 min. Cells were homogenized and glycogen synthesis was determined by scintillation counting as described in 'Materials and methods'. Results are expressed as fold-change of the synthetic capacity determined for control cells. Values represent means ϩ S.D. of three independent determinations (for clarity, S.D. is shown one-sided with variable orientation). (C) Influence of insulin and different inhibitors of GSK-3␤ on total glycogen in cultured hepatocytes. Hepatocytes were cultured in the presence of insulin (Ins
LiCl and SB216763 produced pronounced increases of the levels of hypophosphorylated ␤-catenin as revealed by the anti-active-␤-catenin (anti-ABC) antibody
To determine whether reduced efficacy of L4 at activating ␤-catenin was specific for HEK293 cells, we additionally examined the effects of L4, SB216763 and Wnt-3␣-conditioned media in the neural cell line C17.2 which is known to respond well to activation of Wnt/␤-catenin signalling
In many cases, the ultimate cellular response towards a Wnt stimulus is a change in gene expression patterns [33] . To [66] [67] [68] . As expected, both SB216763 and Wnt-3a enhanced Axin2 expression (Fig. 7, lanes 3, 4 and 8, 9 ). In contrast, L4 failed to stimulate Axin2 transcription at all concentrations tested (Fig. 7, lanes 5-7) . Thus, the lack of Axin2 induction correlates with the lesser capacity of L4 to induce a free pool of ␤-catenin. In summary, L4 is able to evoke a limited cytosolic response of the Wnt/␤-catenin pathway with some accumulation of hypophosphorylated ␤-catenin, but the degree of activation appears to be too low to elicit a nuclear response. Fig. 8A, SB216763 considerably enhanced the ratio of TOPflash/FOPflash within 24 hrs after transfection. In contrast, L4 significantly reduced this ratio below that of controls. Most interestingly, however, when HuH7 cells were exposed to both SB216763 and L4, the stimulation obtained by SB216763 was blocked to a large extent (Fig. 8A) .
Differential induction of TCF-responsive targets by GSK-3␤ inhibitors and L4
In order to obtain information on whether the lack of effect of L4 on expression of Axin2 is solely due to the low degree of ␤-catenin activation or may depend partly or fully on other features of L4, the response of two other TCF-responsive targets was investigated. First, we used a transient transfection assay with the TOPflash reporter in HuH7 cells. The non-responsive reporter FOPflash was used as control. As depicted in
Second, a similar type of experiment was performed in HEK293 cells transfected with the TOPflash reporter. In parallel to determination of TOPflash activity in the presence of control (DMSO), SB216763 (10 M), L4 (10 M) and the combination of both inhibitors the relative amount of ␤-catenin was determined by Western blotting (Fig. S2) . While L4 had no influence on the relative amount of ␤-catenin and on TOPflash activity, it reduced the induction of both parameters by SB216763.
Third, we investigated the influence of these inhibitors on the expression of glutamine synthetase, which has recently been shown to be up-regulated by activating mutations of ␤-catenin [27, 69] or by lithium chloride [27] in hepatoma cells and foetal mouse hepatocytes [70] . As depicted in Fig. 8B , glutamine synthetase specific activity responds well to LiCl (up to 40 mM) in (Fig. 8C) . If, however, SB216763 and L4 were combined, the SB216763-induced increase in enzyme activity was prevented by L4 in a concentration-dependent manner (Fig. 8D) 
-12). Controls were either untreated (LiCl; lanes 1, 2) or received DMSO at a final concentration of 0.8% (SB216763 and L4; lanes 1, 2). Cells were harvested 3 hrs after adding GSK-3 ␤ inhibitors and cell lysates were prepared. After determination of protein concentrations and the addition of GST-␤-catenin calibrator proteins, duplicate samples of each cell lysate were separated by SDS-PAGE, and subsequently transferred onto nitrocellulose. Western blots were sequentially probed with antibodies recognizing (A) active ␤-catenin (anti-ABC), (B) total cellular ␤-catenin and (C) ␣-tubulin. (D) Affinity precipitation to measure a signalling-competent pool of ␤-catenin induced by
Discussion
According to a recent general survey on the specificity of GSK-3␤ inhibitors [22] as well as to results from various original publications [71] [72] [73] [74] exclusive specificity of synthetic inhibitors for this particular kinase is rare despite their considerable structural diversity. Rather, each inhibitor even the most specific ones, namely CT 99021 and AR A014418 [22, 25, 58] [12, 58, 72, [74] [75] [76] [77] [78] . Despite this similarity, however, L4 does inhibit neither CDKs nor PKC which are secondary targets of several ATPcompetitive inhibitors [71, 74] . In contrast, L4 seems to affect to some extent two other kinases, namely JNK-3 and AMPK, which have rarely been described as secondary targets of GSK-3␤ inhibitors.
Second, L4 shows a low cytotoxicity compared with many GSK-3␤ inhibitors particularly with TDZD-8. Because of the complex role of GSK-3␤ in regulating apoptosis [79] [11] [12] [13] 24] , data on the influence on Fig. 10 . We provide evidence that L4 acts through inhibition of a hitherto unknown event downstream to activation of ␤-catenin by dephosphorylation which precedes the occurrence of ␤-catenin in a cellular pool accessible to ECL fishing (Fig. 10) 
